Positive results have been announced by Advanced Life Sciences Holdings, Inc., from its in vitro study to assess the efficacy of Restanza, a broad spectrum medical countermeasure for biodefense to combat multiple high priority bioterror agents.
The study assessed Restanza's efficacy against 30 strains of Burkholderia pseudomallei, which is a serious, life-threatening bacterial pathogen with applications for bioterror.
Significant in vitro activity was shown against clinical and environmental strains of B. pseudomallei as measured by minimal inhibitory concentration, which is the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after 24 hours of incubation.
Restanza also demonstrated positive activity against strains that showed resistance to a azithromycin, a commonly used antibiotic.
"These impressive data provide additional validation of Restanza's broad spectrum of antibacterial activity as a countermeasure for biodefense and highlight its ability to address serious bacterial infections that today are becoming untreatable due to the increasing public health threat of bacterial resistance to currently marketed antibiotics, especially in emerging markets," Michael T. Flavin, Ph.D., chairman and chief executive officer of Advanced Life Sciences, said.
"When these data are added to the substantial body of evidence from previously published studies showing Restanza's demonstrated potent activity in multi-drug resistant pneumonia, tuberculosis, malaria, Lyme disease and sexually transmitted diseases, such as gonorrhea, our belief in Restanza's breakthrough therapeutic potential is significantly strengthened," he said.